Incyte Corporation - Articles and news items

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

EC approves Eli Lilly’s rheumatoid arthritis drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with […]


NICE approves Incyte’s leukaemia drug for routine NHS use

Industry news / 13 February 2017 / Niamh Marriott, Digital Editor

NICE published draft guidance recommending ponatinib (Iclusig, Incyte Corporation) for routine use on the NHS, to treat chronic myeloid leukaemia…

FDA extends review period for Eli Lilly’s rheumatoid arthritis drug

Industry news / 16 January 2017 / Niamh Marriott, Digital Editor

Baricitinib is also being studied in phase 2 trials for atopic dermatitis and systemic lupus erythematosus, and a phase 3 trial for patients…

First patient treated in the Phase III ECHO-301 study

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma…

Phase I/II trial of INCAGN1876 in solid tumours starts

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours…

New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…

Incyte to acquire ARIAD’s European operations for $140m

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialise Iclusig…

Lilly and Incyte announce results from RA-BEACON baricitinib study

Industry news / 31 March 2016 / Victoria White

The study, in patients with rheumatoid arthritis, met its primary endpoint of improved ACR 20 response for baricitinib compared with placebo…

Incyte discontinues JANUS 1 study of ruxolitinib plus capecitabine

Industry news / 11 February 2016 / Victoria White

Incyte has explained that its decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.

Lilly and Incyte submit NDA for baricitinib to the FDA

Industry news / 19 January 2016 / Victoria White

The new drug application (NDA) has been submitted for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis…

Incyte and AstraZeneca announce new lung cancer trial collaboration

Industry news / 11 January 2016 / Victoria White

Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte’s INCB39110 in combination with AstraZeneca’s Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...